Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Intervet Ireland Limited
QV07AB
.
Solvent for parenteral use
POM: Prescription Only Medicine as defined in relevant national legislation
Cats, Dogs
Solvents and diluting agents, incl. irrigating solutions
Immunological - Diluent
Authorised
2003-10-03
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac Solvent 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCES: None EXCIPIENTS: For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Solvent for parenteral use. Clear, colourless liquid. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats and dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Solvent for reconstitution of Nobivac DHP, Nobivac DHPPi, Nobivac Parvo-C, Nobivac Ducat and Nobivac Tricat Trio vaccines. 4.3 CONTRAINDICATIONS Any contra-indications specified for the vaccine for which the solvent is used for reconstitution will apply. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES There are no special warnings, however any warnings specified for the vaccine for which Nobivac Solvent is used as the solvent will apply. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals No special precautions are required for handling the solvent however any recommendations specified for the vaccine for which Nobivac Solvent is used as a solvent will apply. Special precautions to be taken by the person administering the veterinary medicinal product to animals In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _2_ _2_ _/_ _1_ _2_ _/_ _2_ _0_ _1_ _5_ _C_ _R_ _N_ _ _ _7_ _0_ _2_ _2_ _4_ _7_ _3_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _: Read the complete document